Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

It brings Lilly's total investment in Raheen to $2 billion, doubling the investment the company announced in March 2023.

Nina T Hovland, vice president and general manager of Novo Nordisk Ireland, Caitriona Walsh, country president and managing ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in health.

Officials from the Indianapolis-based drugmaker said the Lilly Medicine Foundry will help streamline the process of discovering new medicines and getting them to patients.

Eli Lilly CEO David Ricks signaled he was not interested in such a race and instead is focusing on near-term wins with next-generation GLP-1s and the highly anticipated orforglipron, an obesity ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

He called out Masayoshi Son, CEO of SoftBank; Ted Ogawa, CEO of Toyota Motor North America; Doug Herrington, CEO of Worldwide Amazon Stores; and David Ricks, Eli Lilly CEO, among others, in the crowd.

Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.